← Back to Search

Benzodiazepine

Diazepam for Epilepsy

Phase 1 & 2
Waitlist Available
Led By Jeffrey Britton, MD
Research Sponsored by Mayo Clinic
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial
Must have
Drug-resistant focal epilepsy, having failed 2 previous anti-seizure medications.
Be older than 18 years old
Timeline
Screening 3 weeks
Treatment Varies
Follow Up baseline, 3 months
Awards & highlights

Study Summary

This trial will test whether diazepam reduces seizure frequency in people with a specific type of epilepsy.

Eligible Conditions
  • GAD 65 Antibody-associated Epilepsy

Eligibility Criteria

Inclusion Criteria

You may be eligible if you check “Yes” for the criteria below
Select...
You have epilepsy that doesn't respond to medications and have tried two different medications without success.

Timeline

Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~baseline, 3 months
This trial's timeline: 3 weeks for screening, Varies for treatment, and baseline, 3 months for reporting.

Treatment Details

Study Objectives

Outcome measures can provide a clearer picture of what you can expect from a treatment.
Primary outcome measures
Change in seizure frequency

Trial Design

1Treatment groups
Experimental Treatment
Group I: GAD65 Associated EpilepsyExperimental Treatment1 Intervention
Subjects diagnosed with GAD65 associated epilepsy, serum high-titer GAD65 positivity, trialed and failed at least 2 anti-seizure medications, at least 4 seizures per month will be started on diazepam.
Treatment
First Studied
Drug Approval Stage
How many patients have taken this drug
Diazepam
2016
Completed Phase 4
~3070

Find a Location

Who is running the clinical trial?

Mayo ClinicLead Sponsor
3,176 Previous Clinical Trials
3,758,021 Total Patients Enrolled
22 Trials studying Epilepsy
1,162 Patients Enrolled for Epilepsy
Jeffrey Britton, MDPrincipal InvestigatorMayo Clinic
Kelsey Smith, MDPrincipal InvestigatorMayo Clinic

Media Library

Diazepam (Benzodiazepine) Clinical Trial Eligibility Overview. Trial Name: NCT05361447 — Phase 1 & 2
Epilepsy Research Study Groups: GAD65 Associated Epilepsy
Epilepsy Clinical Trial 2023: Diazepam Highlights & Side Effects. Trial Name: NCT05361447 — Phase 1 & 2
Diazepam (Benzodiazepine) 2023 Treatment Timeline for Medical Study. Trial Name: NCT05361447 — Phase 1 & 2

Frequently Asked Questions

These questions and answers are submitted by anonymous patients, and have not been verified by our internal team.

Are there any unfilled vacancies in this clinical trial?

"No, this particular trial is not looking for new patients at the moment. According to the website clinicaltrials.gov, which last updated information about this study on September 12th, 2022, 242 other trials are actively recruiting participants."

Answered by AI
~14 spots leftby Mar 2025